But let's catch everyone else up to speed on some of the most common side effects of GLP-1s and any long-term risks
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar
An increase in the levels of reduced glutathione, superoxide dismutase, and catalase, alongside a decrease in nitric oxide levels, indicates a positive antioxidant effect of the compound
Despite this, standardized methods to assess these risks and effective preventive strategies remain inadequately studied
Rheumatol Int (2013) 33:182935
Glucagon activation increases energy expenditure (meaning your body burns more calories at rest) and accelerates fat oxidation, particularly in the liver
